Finoriq

Finoriq research workspace

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Historical Metrics

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development. Review CRL valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Company
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
Ticker
CRL
Market Cap
$10.7B
Latest Price
$221.11
Industry
Biotech & Pharma

Open insider transactions

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Current Valuation Metrics

Static valuation preview for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL). Market data retrieved 2026-07-08. Filing currency USD.

MetricValueSource
P/SMarket cap divided by latest TTM revenue.2.67xRevenue | TTM Q1 2026
P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow.17.7xOperating Cash Flow | TTM Q1 2026
Earnings YieldLatest TTM net income divided by market cap.-1.7%Net Income | TTM Q1 2026
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.5.6%Operating Cash Flow | TTM Q1 2026
Price / BookMarket cap divided by stockholders' equity.3.66xStockholders' Equity | Q1 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.